Joint ePRO Initiative Delivers Ready-to-Use, Patient-Centric Solutions to Speed Trial Times and Enhance Patient Engagement
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and ICON plc, (NASDAQ:ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials. By combining Medidata’s best-in-class technology with ICON’s ready-to-use, pre-validated surveys, the new offering provides sponsors with an ePRO solution that reduces costs, saves time and enhances patient engagement.
Medidata Patient Cloud™, an innovative ePRO solution for patient-centric data capture, significantly simplifies trial setup through its configurable interface with the Medidata Clinical Cloud™. ICON brings ready-to-go, pre-validated patient input instruments for fast clinical trial deployment. These productivity enhancements, combined with the Patient Cloud interface available as a mobile app, create an industry-leading solution for capturing patient input in clinical research.
“We are pleased to extend our partnership with Medidata,” commented Dermot Kenny, Executive Vice President, Global Clinical and Data Operations. “Their innovative technology, together with ICON’s market-leading expertise, creates a solution that will help customers reduce study timelines and makes it easier for patients to record their experiences.”
Available on any iOS® device and automatically unified with Medidata’s platform, Patient Cloud provides electronic patient questionnaire and diary functionality in a model that simplifies the setup process, freeing research organizations from the burdens of custom software and proprietary devices. And in simplifying the data capture and patient participation processes, Medidata’s ePRO solution is transforming the clinical trial experience for study participants at a time when capturing the patient voice is becoming increasingly important.
“We’re thrilled to be expanding this partnership and share ICON’s commitment to bringing the voice of the patient to clinical research,” said Glen de Vries, Medidata’s president. “Together, we’re changing how the industry conducts clinical trials by making ePROs applicable to a wider array of studies, reducing the work required to use them and eliminating pain points such as equivalencies and other complicated processes.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.